Portrait of a patient with chronic heart failure with preserved ejection fraction and assessment of survival considering comorbid pathology

   Introduction. Chronic heart failure (CHF) is a clinical syndrome that is a widespread complication of cardiovascular diseases. The majority of patients with CHF are individuals with a preserved left ventricular ejection fraction (LVEF ≥ 50 %). The number of such patients is increasing every year, while there is no effective drug therapy for this disease.

   Objective. To create a portrait of a patient with CHF and analyze the 10-year survival rates on the Charlson Comorbidity Index scale in a cohort of patients, considering gender and age characteristics.

   Materials and methods. Patients with CHF participated in the study. Demographic, anamnestic, and laboratory instrumental data were considered. The 10-year survival rate was assessed using the Charlson Comorbidity Index scale.

   Results. The average age of the subjects was 62 ± 26 years. Among the pathologies of the cardiovascular system, hypertension prevailed — 274 people (100 %), angina pectoris — 184 people (67 %), and atrial fibrillation (AF) — 100 people (36 %). Among the studied 14 people. (5 % of patients) had a history of chronic obstructive pulmonary disease (COPD), 8 people (3 %) had bronchial asthma (BA). 88 subjects (33 %) suffered a cardiovascular catastrophe. Among all the studies, the 10-year survival rate on the Charlson Comorbidity Index scale of less than 50 % was detected in 174 people (63.5 %), among whom 106 women predominated (39 %).

   Conclusion. Portrait of a typical patient with CHF: male or female patient aged 60–69 years. Of the concomitant pathologies, most often those who are overweight / obese, hypertension, angina pectoris, atherosclerosis, AF, diabetes mellitus, who have had a history of myocardial infarction and/or stroke/transient ischemic attack. Older women (from 60 to 74 years old) are more likely to have a survival index of less than 50 % on the Charlson Comorbidity Index scale.

1. Larina VN, Skiba IK. Prospects for predicting and preventing the heart failure deterioration : an analytical review. Russian Journal of Cardiology. 2024;29(9):5854. (In Russ.) doi: 10.15829/1560-4071-2024-5854. EDN: NLOUYV.

2. Galyavich AS, Tereshchenko SN, Uskach TM, et al. 2024 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology. 2024;29(11): 6162. (In Russ.) doi: 10.15829/1560-4071-2024-6162. EDN: WKIDLJ.

3. Drapkina OM, Kontsevaya AV, Kalinina A.M, et al. Comorbidity of patients with noncommunicable diseases in general practice. Eurasian guidelines. Cardiovascular Therapy and Prevention. 2024;23(3):3996. (In Russ.) doi: 10.15829/1728-8800-2024-3996. EDN AVZLPJ.

4. Shevtsova VI, Pashkova AA, Kolpacheva MG, et al. The level of the biomarker Galectin-3 in patients with chronic heart failure. Scientific and Medical Bulletin of the Central Chernozem region. 2024(96):75-81. (In Russ.) doi: 10.18499/1990-472X-2024-25-2-75-81. EDN XLPNKQ.

5. Kobalava ZhD, Konradi AO, Nedogoda SV, et al. 2024 Clinical practice guidelines for Hypertension in adults. Russian Journal of Cardiology. 2024;29(9):6117. (In Russ.) doi: 10.15829/1560-4071-2024-6117. EDN: GUEWLU

6. Ding N, Shah AM, Blaha MJ, et al. Cigarette Smoking, Cessation, and Risk of Heart Failure With Preserved and Reduced Ejection Fraction. J Am Coll Cardiol. 2022 Jun 14;79(23):2298-2305. doi: 10.1016/j.jacc.2022.03.377.

7. Drapkina OM, Skripnikova IA, Yaralieva EK, Myasnikov RP. Body composition in patients with heart failure. Cardiovascular Therapy and Prevention. 2022;21(12):3451. (In Russ.) doi: 10.15829/1728-8800-2022-3451

8. Jenča D, Melenovský V, Stehlik J, et al. Heart failure after myocardial infarction: incidence and predictors. ESC Heart Fail. 2021 Feb;8(1):222-237. doi: 10.1002/ehf2.13144.

9. Charlson M, Wells MT, Ullman R, et al. The Charlson comorbidity index can be used prospectively to identify patients who will incur high future costs. PLoS One. 2014 Dec 3;9(12):e112479. doi: 10.1371/journal.pone.0112479.